Farmacéuticos Comunitarios. 2017 Sep 30; 9(3):20-24 DOI: 10.5672/FC.2173-9218.(2017/Vol9).003.05

The “Revisa®” Project: The Impact of the Medicines Use Review Service in Spain. Time and Costs Report

Gómez Bermúdez E1, García-Agua Soler N2, Jódar Sánchez F3, Baixauli Fernández VJ4
1. Doctor en Farmacia. Farmacéutico comunitaria. Miembro de la subcomisión de RUM de SEFAC 2. Licenciada en Farmacia. Doctora por la Universidad de Málaga. Departamento de Farmacología y Pediatría. Facultad de Medicina. Universidad de Málaga 3. Doctor por la Universidad de Granada. Fundación Pública Andaluza para la Gestión de la Investigación en Salud en Sevilla. 4. Doctor en Farmacia. Farmacéutico comunitario. Miembro de la subcomisión de RUM de SEFAC
Gómez E, García-Agua N, Jódar F, Baixauli VJ. Proyecto ‘Revisa®’. Impacto del servicio de revisión del uso de los medicamentos en España. Informe de tiempos y costes. Farmacéuticos Comunitarios. 2017 Sep 30; 9(3):20-24 DOI: 10.5672/FC.2173-9218.(2017/Vol9).003.05
Abstract : 

In 2013, the Sociedad Española de Farmacia Familiar y Comunitaria (SEFAC) [Spanish Society of Community Pharmacy] launched the Revisa® project. Managed by the Medicines Use Review (MUR) Subcommittee, part of the Professional Services Committee, the project takes its inspiration from the British MUR service and seeks to introduce a similar service throughout Spain. 

Since then, training courses have been delivered, specification documents drawn up, and protocols standardized, to enable community pharmacy to deliver the service to the public in an appropriate and consistent manner. A module to manage the service has also been developed in SEFAC e_XPERT, a computer program designed by SEFAC to manage professional pharmaceutical services.

In 2016, SEFAC completed the first research study linked to the medicines use review service, designed to pilot its work in pharmaceutical practice. 

This report presents the time and cost results obtained by analyzing the data collected as part of the Revisa® project from 64 pharmacies in Spain between March and July 2016. The aim is to provide community pharmacy with the information required to establish the appropriate fees for the delivery of this service, based on evidence obtained from pharmaceutical practice.

Article download link: